RxDoctor Payments Data

Shanee Owens, NP

Family · Chattanooga, TNNPI 1629248505

Payments from drug & device makers

$1,108in general payments, 2019–2025

Across 38 payments — averaging $29.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$753
  • Novo Nordisk$78
  • AstraZeneca$74
  • Lilly USA, LLC$55
  • Bayer$53
  • GSK$23
  • plus $72 from 4 others

What the payments were for

  • Food & beverage$1,108100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)21$753
Novo Nordisk5$78
AstraZeneca1$74
Lilly USA, LLC3$55
Bayer3$53
GSK1$23
Amgen1$21
Exact Sciences1$21
Merck1$17
Biohaven Pharmaceuticals, Inc.1$12

How this compares

$1,108 in reported general payments places this provider in the 65th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$17,671
Medicare patients
94
Services billed
320

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$96,438
TrulicityDulaglutide20$44,302
JardianceEmpagliflozin25$33,935
MounjaroTirzepatide30$33,116
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$23,149
LinzessLinaclotide31$21,036
JanuviaSitagliptin Phosphate19$20,864
FarxigaDapagliflozin Propanediol28$20,846
RybelsusSemaglutide16$20,477
XareltoRivaroxaban25$14,336
EliquisApixaban19$13,220
TrintellixVortioxetine Hydrobromide14$9,341
Lantus SolostarInsulin Glargine,hum.Rec.Anlog72$8,364
VyvanseLisdexamfetamine Dimesylate18$6,989
SymbicortBudesonide/Formoterol Fumarate18$4,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$78$116,91580 claims
Lilly USA, LLCTrulicity, Mounjaro$55$77,41850 claims
AstraZenecaFarxiga, Symbicort$74$24,97946 claims
GSKTrelegy Ellipta$23$23,14929 claims
AbbVieLinzess$753$21,03631 claims
MerckJanuvia$17$20,86419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,706 family providers in Tennessee.

Other family in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →